PEACHI header v5 FP7-gen-RGB EU flag

Prevention of Hepatitis C Virus (HCV) and HIV-1 Co-Infections

A collaborative project financed by the EC Framework Programme 7

Recent Publications by PEACHI consortium members

von Delft A et al., Vaccine. 2018 Jan 4;36(2):313-321 - The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.


Hancock G et al., J Int AIDS Soc. 2017 May 19;20(1):21171 - Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.


Ewer et al., Curr Opin Immunol 2016 Jun 7; 41: 47-54 - Viral vectors as vaccine platforms: from immunology to impact.


von Delft A et al., Gut 2015 Jun; 0:1–12 – The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.


Hancock G et al., PLoS Pathog. 2015 Feb 27;11(2) - Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses


Kelly C et al., Eur J Immunol. 2015 Jan;45(1):309-16 – Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes


Swadling L et al., Sci Transl Med. 2014 Nov 5;6(261):261ra153 – A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory


Capone S et al., Mol Ther. 2014 May;22(5):1039-47 – Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates


Borthwick N et al., Mol Ther. 2014 Feb;22(2):464-75 – Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1